Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-09-01), WuXi XDC Cayman's share price is HK$71.25.
WuXi XDC Cayman's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1.30. Therefore, WuXi XDC Cayman's PE Ratio for today is 54.72.
During the past 6 years, WuXi XDC Cayman's highest PE Ratio was 225.68. The lowest was 31.43. And the median was 57.61.
WuXi XDC Cayman's EPS (Diluted) for the
six
months ended in Dec. 2025 was HK$0.61.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1.30.
During the past 12 months, WuXi XDC Cayman's average EPS without NRIGrowth Rate was 34.20% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 74.40% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 126.50% per year.
During the past 6 years, WuXi XDC Cayman's highest 3-Year average EPS without NRI Growth Rate was 157.40% per year. The lowest was 74.40% per year. And the median was 152.00% per year.
WuXi XDC Cayman's EPS (Basic) for the
six
months ended in Dec. 2025 was HK$0.72.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1.47.
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.
WuXi XDC Cayman PE Ratio Related Terms
WuXi XDC Cayman PE Ratio Historical Data
* Premium members only.
The historical data trend for WuXi XDC Cayman's PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, WuXi XDC Cayman's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman PE Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's PE Ratio distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's PE Ratio falls into.
The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
WuXi XDC Cayman's Share Price of today is HK$71.25.
For company reported semi-annually, WuXi XDC Cayman's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$1.30.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
WuXi XDC Cayman (HKSE:02268) has a PE Ratio of 54.72 as of Sep. 01, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on WuXi XDC Cayman and its competitors. This is near median its historical median of 57.61. Over the past decade, WuXi XDC Cayman's PE Ratio has ranged from 31.43 to 225.68.
Is WuXi XDC Cayman's PE Ratio too high?
WuXi XDC Cayman's current PE Ratio of 54.72 is near median its 10-year median of 57.61. Over the past 10 years, this metric has ranged from a low of 31.43 to a high of 225.68. Overall, WuXi XDC Cayman has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's PE Ratio compare to TMO and DHR?
WuXi XDC Cayman's PE Ratio of 54.72 can be compared against companies in the Medical Diagnostics & Research industry. Historically, WuXi XDC Cayman's own PE Ratio has ranged from 31.43 to 225.68 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Medical Diagnostics & Research company?
A good PE Ratio depends on the Medical Diagnostics & Research industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on WuXi XDC Cayman and its competitors. WuXi XDC Cayman's current PE Ratio is 54.72, which is near median its own 10-year median of 57.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (HKSE:02268) has a current PE Ratio of 54.72. The current PE Ratio is 54.72, which is near median its 10-year median of 57.61. WuXi XDC Cayman's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For WuXi XDC Cayman (HKSE:02268), the current PE Ratio is 54.72 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
50GF Score
Get the complete analysis for HKSE:02268
PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02268 has been successfully added to your 
